Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Blood blood.2025031480.

https://doi.org/10.1182/blood.2025031480

Published: 2025

Includes: Supplemental data

Journal Articles

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Blood (2025) 146 (Supplement 1): 5183.

https://doi.org/10.1182/blood-2025-5183

Published: 2025

Journal Articles

Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.

Arjan Van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Janine Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Alex Karlsson-Parra, Tariq Mughal, Bjorn Gjertsen

Blood (2025) 146 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2025-1647

Published: 2025

Journal Articles

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Blood (2025) 146 (Supplement 1): 343.

https://doi.org/10.1182/blood-2025-343

Published: 2025

Journal Articles

Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Lukas H. Haaksma, Raffaele Palmieri, Jesse M. Tettero, Tom Reuvekamp, Lok Lam Ngai, Costa Bachas, Angèle Kelder, Willemijn J. Scholten, Patrycja Gradowska, Valentina Arena, Anderson Simione, Luca Maurillo, Adriano Venditti, Bob Lowenberg, Gert J. Ossenkoppele, David C. de Leeuw, Maura R. V. Ikoma-Colturato, Francesco Buccisano, Jacqueline Cloos

Blood (2024) 144 (Supplement 1): 4329.

https://doi.org/10.1182/blood-2024-203158

Published: 2024

Journal Articles

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Arjan A. van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2024) 144 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2024-201374

Published: 2024

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls

Jesse M. Tettero, Maaike Heidinga, Tim R. Mocking, Glenn Fransen, Ezra S Beerman, Angèle Kelder, Willemijn Scholten, Alexander N. Snel, Lok Lam Ngai, Costa Bachas, Arjan A. Van de Loosdrecht, Gert Ossenkoppele, David C. de Leeuw, Jeroen J.W.M. Janssen, Jacqueline Cloos

Blood (2023) 142 (Supplement 1): 1559.

https://doi.org/10.1182/blood-2023-179242

Published: 2023

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, Kazem Nasserinejad, Thomas Pabst, Johan A. Maertens, Dimitri A. Breems, Markus G Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Lowenberg, Gerwin A. Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen, Jurjen Versluis

Blood (2022) 140 (Supplement 1): 127–129.

https://doi.org/10.1182/blood-2022-158137

Published: 2022

Journal Articles

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Margot S.F. Roeten, Johan van Meerloo, Zinia Kwidama, Gaye Jenkins, Suzanne N. van Dijk, David T. Teachey, Meenakshi Devidas, Mignon L. Loh, Gertjan J.L. Kaspers, Sonja Zweegman, Gerrit Jansen, Jacqueline Cloos, Terzah M. Horton

Blood (2022) 140 (Supplement 1): 9183–9184.

https://doi.org/10.1182/blood-2022-162412

Published: 2022

Journal Articles

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A. Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griskevicius, Jeroen J.W.M. Janssen, Gunnar Juliusson, Johan A. Maertens, Markus G Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter JM Valk, Bob Lowenberg, Gert J. Ossenkoppele, Jacqueline Cloos

Blood (2022) 140 (Supplement 1): 2027–2029.

https://doi.org/10.1182/blood-2022-157009

Published: 2022

Journal Articles

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Sören Lehmann, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 1714–1715.

https://doi.org/10.1182/blood-2022-162169

Published: 2022

Journal Articles

Decreased Embryonic Splicing Repressor Expression Enhances Splicing Modulator Sensitivity in Pediatric Acute Myeloid Leukemia Stem Cells

Inge Van Der Werf, Kathleen Steel, Phoebe Mondala, Larissa Balaian, Jacqueline Cloos, Gertjan J.L. Kaspers, James La Clair, Peggy Wentworth, Kathleen Fisch, Leslie Crews, Thomas Whisenant, Michael Burkart, Mary Donohoe, Catriona Jamieson

Blood (2022) 140 (Supplement 1): 3354–3355.

https://doi.org/10.1182/blood-2022-171145

Published: 2022

Journal Articles

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Blood (2022) 140 (Supplement 1): 9125–9127.

https://doi.org/10.1182/blood-2022-157753

Published: 2022

Journal Articles

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Marij J.P. Welters, Sjoerd H. van der Burg, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 3410–3411.

https://doi.org/10.1182/blood-2022-163116

Published: 2022

Journal Articles

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Blood (2021) 138 (26): 2753–2767.

https://doi.org/10.1182/blood.2021013626

Published: 2021

Includes: Supplemental data

Journal Articles

Deregulation of Splicing in Pediatric Acute Myeloid Stem and Progenitor Cells

Blood (2021) 138 (Supplement 1): 2227.

https://doi.org/10.1182/blood-2021-154120

Published: 2021

Journal Articles

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva Maria Wagner, Uwe Platzbecker, Tobias A. W. Holderried, Janine van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2021) 138 (Supplement 1): 1274.

https://doi.org/10.1182/blood-2021-148333

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Leukemic Phenotype Determines Prognostic Relevance of Limit of Quantification for Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Impact of Hemodilution on Measurable Residual Disease Measured Via Flow-Cytometry in Acute Myeloid Leukemia Analyzed Using Subsequent Pulls

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children's Oncology Group Trial AALL1231

Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Decreased Embryonic Splicing Repressor Expression Enhances Splicing Modulator Sensitivity in Pediatric Acute Myeloid Leukemia Stem Cells

Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Deregulation of Splicing in Pediatric Acute Myeloid Stem and Progenitor Cells

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only